Merck and Cidara Therapeutics, Inc., have entered into a definitive agreement under which Merck will acquire Cidara for $9.2 ...

Merck has entered a definitive agreement to acquire Cidara Therapeutics, a biotechnology company developing drug-Fc conjugate ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Cidara Therapeutics, Inc. (Nasdaq: CDTX) ...

In a significant move to bolster its portfolio, Merck has announced its acquisition of Cidara Therapeutics for nearly $9.2 billion. This deal, which aims to secure access to an ex ...

Merck has made several big-ticket deals this year, led by its $10 billion buyout of Verona Pharma in July, giving the pharma ...

Cidara Therapeutics ( ($CDTX) ) has provided an update. On November 13, 2025, Cidara Therapeutics entered into a merger agreement with Merck, ...

Merck & Co. is spending $9.2 billion for Cidara Therapeutics and its lead influenza antiviral that was dropped by Johnson & ...

Cidara Therapeutics (CDTX) stock rocketed higher on Friday after the biotechnology company announced it will be acquired by ...

Merck announced the $9.2 billion deal with Cidara on Friday, sending Cidara's stock (CDTX) soaring 106% in recent morning trading, enough to make it the biggest gainer on the major U.S. exchanges. The ...

Merck & Co., Inc. acquires Cidara Therapeutics, Inc. for $9.2bn, boosting its pipeline with CD388's strong flu data. Click ...

Phase 3 accelerated approval trial of IFx-2.0 as adjunctive therapy with Keytruda® (pembrolizumab) as a first-line therapy ...